| European Case Law Identifier: | ECLI:EP:BA:2016:T019415.20160309 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 09 March 2016 | ||||||||
| Case number: | T 0194/15 | ||||||||
| Application number: | 05076131.1 | ||||||||
| IPC class: | A61K 39/395 A61K 38/17 A61K 31/505 A61P 37/00 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | D | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Anti-TNF antibodies and methotrexate in the concomitant treatment of autoimmune diseases | ||||||||
| Applicant name: | The Kennedy Trust for Rheumatology Research | ||||||||
| Opponent name: | Celltrion, Inc. (opposition withdrawn) Althausen, Sonja Hospira UK Limited (opposition withdrawn) AbbVie Inc. Eiseler, Alice |
||||||||
| Board: | 3.3.04 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Admissibility of appeal - (yes) Validity of transfer of opponent status - (no) Remittal to the opposition division - (yes) |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t150194eu1.html
Date retrieved: 17 May 2021